HighTide Therapeutics, Inc. (HKG: 2511), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM)…
Browsing: Clinical Trials
Over 1,000 investment and business matching meetings, MoUs to support healthcare enterprises to go global The sixth Asia Summit on Global…
China Medical System Holdings Limited (CMS or the Group) is pleased to announce that, the Group through its wholly-owned subsidiary…
China Medical System Holdings Limited (the Group or CMS) is pleased to announce that the New Drug Application (NDA) in…
Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual…
Guoyuan International issued a research report on Essex Bio-Technology on 1 April 2026. Essex posted steady operating performance growth in…
Across the landscape of global biotech companies, the appointment of a senior executive often serves as a “barometer”—offering insights into…
On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its…
CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by…
Essex Bio-Technology Limited (EssexBio or the Company; HKG: 1061) today announces its successful participation in the 41st Asia-Pacific Academy of…
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine OBI Pharma (4174.TWO) announced that it…
PromiCell, Inc. (the Company), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients,…
Everest Medicines today announced that the first patient has been enrolled in a global multi-center Phase I clinical trial of…
In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies,…
Essex Bio-Technology Limited (Essex or the Group, HKG: 1061) is pleased to announce that a Biologics License Application (BLA) for…
On July 15 2025, to mark the successful secondary listing of China Medical System Holdings Limited (“CMS” or the “Group”)…
Technology Co-Developed by the U.S. Department of Veteran Affairs and Emory University Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the…
Hua Medicine (the Company, HKG: 2552) announced today that the Company presented the latest research results of dorzagliatin, its global…
Pneumonia is a form of acute respiratory infection, that is common in all age groups and can cause mild to…
– Offer price of S$0.25 per share is at an attractive premium of 61.3% over the last traded price being…